MIRA INFORM REPORT

 

 

Report Date :

19.12.2007

 

IDENTIFICATION DETAILS

 

Name :

JERUSALEM PHARMACEUTICALS CO. LTD.

 

 

Registered Office :

P.O. Box 3570, Nablus Main Road, Al Bireh, Ramallah Palestinian Authority

 

 

Country :

Israel

 

 

Date of Incorporation :

1969

 

 

Legal Form :

Public Limited Company

 

 

Line of Business :

Importers and marketers of pharmaceuticals and cosmetics products, including ethical generic pharmaceuticals, OTC preparations and nutritional supplements.

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Maximum Credit Limit :

US$ 350,000

 

 

Status :

Satisfactory

 

 

Payment Behaviour :

No Complaints

 

 

Litigation :

Clear


Correct Name

 

JERUSALEM PHARMACEUTICALS CO. LTD.

 

 

Also known as

 

JEPHARM

 

 

address

 

P.O. Box 3570

Nablus Main Road

Al Bireh

RAMALLAH PALESTINIAN AUTHORITY

Telephone         972 2 240 65 50

Fax                   972 2 240 32 46

 

 

HISTORY

 

Originally established as a foreign private limited company, registered in the Palestinian Authority established in 1969 (registration number not forthcoming – see NOTE at bottom).

 

In 1978, converted into a public limited company.

 

At a later stage, shares begun to be traded by the public.

 

 

SHARE CAPITAL

 

Paid up capital JOD 5,000,000 (5,000,000 shares of JOD 1.00 each).

 

 

SHAREHOLDERS

 

1.         Mohamed Masrouji, 7%

2.         Shares are also traded on the Palestinian Stock Exchange (symbol: JPH).

 

 

DIRECTORS

 

1.    Mohamed Masrouji, Chairman and General Manager,

2.     Ibrahim Taweel,
3.     Dr. Rana Husseini,
4.     Dr. Nidal Kamal,
5.     Dr. Darwish Assali,
6.     Dr. Ezzeldin Abu Maizar,
7.     Buthaina Duqmaq,
8.     Iyad Masrouji,
9.     Ghazi Mushtaha.

 

 

BUSINESS

 

Importers and marketers of pharmaceuticals and cosmetics products, including ethical generic pharmaceuticals, OTC preparations and nutritional supplements.

 

Sole local representatives of PAROUR, of France.

 

Operating from a premises on a large area in the Nablus Main Road, Al Bireh, Ramallah, West Bank, Palestinian Authority.

 

Having 260 employees.

 

 

MEANS

 

Data from the B/S as of 30.09.2007 (in Jordanian Dinar):

Total assets: JOD 21,724,374

Total liabilities: JOD 3,090,893

Equity: JOD 18,633,481

 

(Note: 1.0 JOD = US$ 1.42 on 18.12.2007)

 

 

ANNUAL SALES

 

2005 sales claimed to be US$ 13,000,000.

2006 sales claimed to be US$ 12,000,000.

2007 sales claimed to be US$ 13,500,000.

 

Sales for the first 9 months of 2007 were JOD 6,452,121, making a net profit of JOD 1,261,361.

 

 

BANKERS

 

Arab Bank Plc., Ramallah Branch, Ramallah, West Bank, Palestinian Authority.

Bank of Palestine Ltd., Ramallah Branch (Tannos building), West Bank, Palestinian Authority.

 

 

CHARACTER AND REPUTATION

 

Nothing unfavorable learned.

 

Subject is the largest pharmaceuticals company in the Palestinian Territories.

 

Subject is ISO 9001 and ISO 14001 certified.

 

During 2004, the Palestinian economy started to recover for the first time since the deterioration in the political situation in the region in October 2000.

 

According to researches, GDP per capita in the Palestinian authority in 2004 summed at US$ 1,200, which is still lower than the GDP in 1999, which reached US$ 1,500. GDP of the Palestinian Authority in 2004 was US$ 4.5 billion, 10% increase from 2003. Other positive figures were 27% increase in exports and 23% increase in imports.

 

However, the World Bank Report from 2006 states that year 2006 has been disastrous and one of the worst years in their economic history, following the rising of the Hamas government. It led to the suspension of donations and financial aid from the Western world, as well as to internal conflict, including violence, between the Hamas supporters and those of the Phatah movement.

 

According to experts reports from December 2006, total GDP of the Palestinian Economy in 2006 was US$ 3 billion, and deteriorated to lower than US$ 1,000 GDP per capita.

 

The Palestinian total annual export is evaluated at US$ 0.5 billion. The industrial activity turnover is evaluated at US$ 1.5 billion (data source as of July 2007), with some 80,000 employees.

 

Unless a drastic change occurs in the political environment, the World Bank forecasts a negative growth rate of 2% per annum.

 

 

SUMMARY

 

Good for trade engagements.

 

Maximum unsecured credit recommended US$ 350,000.

 

 

NOTE

 

So far we were unable to confirm subject's registration number. As it is now a holiday in the Palestinian Authority, we shall contact subject's officials next week and update you accordingly.

 

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Unfavourable & favourable factors carry similar weight in credit consideration. Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

NR

In view of the lack of information, we have no basis upon which to recommend credit dealings

No Rating

 

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

 

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions